Larimar Therapeutics, Inc. (LRMR)
| Market Cap | 372.65M +177.1% |
| Revenue (ttm) | n/a |
| Net Income | -166.01M |
| EPS | -2.09 |
| Shares Out | 104.38M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,516,758 |
| Open | 3.450 |
| Previous Close | 3.530 |
| Day's Range | 3.400 - 3.580 |
| 52-Week Range | 1.800 - 6.420 |
| Beta | 0.91 |
| Analysts | Strong Buy |
| Price Target | 15.88 (+344.82%) |
| Earnings Date | May 14, 2026 |
About LRMR
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for LRMR stock is "Strong Buy." The 12-month stock price target is $15.88, which is an increase of 344.82% from the latest price.
News
Larimar Therapeutics price target lowered to $12 from $13 at Wedbush
Wedbush lowered the firm’s price target on Larimar Therapeutics (LRMR) to $12 from $13 and keeps an Outperform rating on the shares. Most notable in the update, Larimar remains on…
Larimar Therapeutics price target lowered to $12 from $13 at Wedbush
Wedbush lowered the firm’s price target on Larimar Therapeutics (LRMR) to $12 from $13 and keeps an Outperform rating on the shares. Larimar remains on track to start its rolling…
Larimar Therapeutics reports Q1 EPS (31c), consensus (57c)
“We have strong momentum as we advance nomlabofusp towards potential approval for the treatment of adults and children with Friedreich’s ataxia. Our ongoing engagement with the U.S. Food and Drug…
Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update
Intending to initiate rolling BLA seeking accelerated approval with submission of nonclinical and clinical modules in June 2026; submission of the final modules including the CMC module expected in se...
Larimar Therapeutics Earnings release: Q1 2026
Larimar Therapeutics released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Larimar Therapeutics Quarterly report: Q1 2026
Larimar Therapeutics has published its Q1 2026 quarterly earnings report on May 14, 2026.
Larimar Therapeutics Slides: Investor presentation
Larimar Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 14, 2026.
Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich's Ataxia
BALA CYNWYD, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare disea...
Larimar Therapeutics Proxy statement: Proxy filing
Larimar Therapeutics filed a proxy statement on April 20, 2026, providing details for shareholder voting and corporate governance matters.
Larimar Therapeutics Proxy statement: Proxy filing
Larimar Therapeutics filed a proxy statement on April 10, 2026, providing details for shareholder voting and corporate governance matters.
Larimar Therapeutics price target raised to $13 from $12 at Wedbush
Wedbush raised the firm’s price target on Larimar Therapeutics (LRMR) to $13 from $12 and keeps an Outperform rating on the shares. Overall, the Q4 update was as anticipated as…
Larimar Therapeutics reports Q4 EPS (73c), consensus (55c)
As of December 31, 2025, the company had cash, cash equivalents and marketable securities totaling $136.9M together with net proceeds of $107.6M from the February 2026 public offering. The company…
Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
* Pro forma cash, cash equivalents, and marketable securities of $244.5 million reflects $136.9 million of cash, cash equivalents and marketable securities as of December 31, 2025 combined with the $1...
Larimar Therapeutics Annual report: Q4 2025
Larimar Therapeutics has published its Q4 2025 annual report on March 19, 2026.
Larimar Therapeutics Earnings release: Q4 2025
Larimar Therapeutics released its Q4 2025 earnings on March 19, 2026, summarizing the period's financial results.
Larimar Therapeutics Transcript: The Citizens Life Sciences Conference 2026
A novel protein replacement therapy for Friedreich's ataxia shows promising efficacy and safety, with strong biomarker correlations and regulatory momentum. FDA engagement has been collaborative, with a BLA submission planned for June and financial runway secured into 2027.
Larimar Therapeutics Transcript: Leerink Global Healthcare Conference 2026
Breakthrough Therapy designation was achieved, with regulatory alignment on frataxin as a surrogate endpoint and a global Phase III trial set to begin U.S. enrollment in Q2. The focus is on pediatric patients, with a flexible market strategy and promising efficacy data compared to competitors.
Larimar Therapeutics Slides: Corporate presentation
Larimar Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on March 10, 2026.
Larimar Therapeutics to Participate in Upcoming Investor Conferences in March
BALA CYNWYD, Pa., March 04, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare disea...
Larimar Therapeutics price target raised to $12 from $11 at Wedbush
Wedbush raised the firm’s price target on Larimar Therapeutics (LRMR) to $12 from $11 and keeps an Outperform rating on the shares. The firm notes that last week, the company…
Larimar Therapeutics 20M share Spot Secondary priced at $5.00
The deal size was increased to $100M from $75M and priced at midpoint of $4.75-$5.25 range. JPMorgan and Guggenheim are acting as joint book running managers for the offering. Published…
Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering
BALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare dise...
Larimar Therapeutics $75M Spot Secondary price range $4.75-$5.25
JPMorgan and Guggenheim are acting as joint book running managers for the offering.
Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering
BALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare dise...
Larimar Therapeutics price target raised to $14 from $12 at Citi
Citi raised the firm’s price target on Larimar Therapeutics (LRMR) to $14 from $12 and keeps a Buy rating on the shares.